Neurocrine fleshes out its PhIII case for valbenazine; Avrobio adds to gene therapy pipeline
→ Neurocrine has already posted the key late-stage data that it took to the FDA in building a case for Ingrezza (valbenazine) as a new therapy for tardive dyskinesia. But now it’s published the full set of data in its favor, including a note that its drug scored for 40% of the patients in the drug arm who registered at least a 50% improvement in AIMS dyskinesia score, compared to 8.7% of those on placebo. Neurocrine is facing a head-to-head fight with a new drug from Teva, and a number of analysts think the smaller biotech has a clear shot at dominating the sector. The PDUFA date for the breakthrough therapy is April 11.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.